[1]杨明娜 苏俊辉 张小龙 潘有贵 肖莉彬 何怡婧 李丽喜 靳令经.原发性与面瘫后面肌痉挛患者面部异常运动A型肉毒毒素的治疗效果对比研究[J].卒中与神经疾病杂志,2019,26(01):77-81.[doi:10.3969/j.issn.1007-0478.2019.01.018]
　Yang Mingna,Su Junhui,Zhang Xiaolong,et al.Comparative study of therapeutic effects of botulinum toxin type A on abnormal facial movement of primary and post paralytic hemifacial spasm[J].Stroke and Nervous Diseases,2019,26(01):77-81.[doi:10.3969/j.issn.1007-0478.2019.01.018]
点击复制

原发性与面瘫后面肌痉挛患者面部异常运动A型肉毒毒素的治疗效果对比研究()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第26卷
期数:
2019年01期
页码:
77-81
栏目:
论 著
出版日期:
2019-02-26

文章信息/Info

Title:
Comparative study of therapeutic effects of botulinum toxin type A on abnormal facial movement of primary and post paralytic hemifacial spasm
文章编号:
1007-0478(2019)01-0077-05
作者:
杨明娜 苏俊辉 张小龙 潘有贵 肖莉彬 何怡婧 李丽喜 靳令经
200065 上海,同济大学附属同济医院神经内科[杨明娜 苏俊辉 张小龙 潘有贵 肖莉彬 何怡婧 李丽喜 靳令经(通信作者)]
Author(s):
Yang Mingna; Su Junhui; Zhang Xiaolong; et al
Department of Neurology,Tongji Hospital of Tongji University,Shanghai 200065
关键词:
联带运动 原发性面肌痉挛 面瘫后面肌痉挛 A型肉毒毒素 病例对照研究
Keywords:
Synkinesis Primary hemifacial spasm Post-paralytic hemifacial spasm Botulinum toxin type A Case control study
分类号:
R745.1+2
DOI:
10.3969/j.issn.1007-0478.2019.01.018
文献标志码:
A
摘要:
目的 探讨A型肉毒毒素(botulinum toxin type A,BoNT-A)治疗原发性及面瘫后面肌痉挛患者痉挛及伴随联带运动的疗效差异。方法 选取2009年1月-2018年7月具有联带运动的面瘫后面肌痉挛患者12例,按照1:2配比性别无差异且具有联带运动的原发性面肌痉挛患者24例,分析2组BoNT-A治疗后痉挛严重程度以及伴随联带运动的改善差异。结果 面瘫后及原发性面肌痉挛患者在起效时间[(4.38±2.17)vs.(4.67±4.14)d],维持时间[(3.83±2.94)vs.(4.96±2.48)d],注射剂量[(31.35±12.30)vs.(26.98±8.75)U]方面无明显差异(P>0.05)。原发性面肌痉挛组患者满意度显著较高(84.79±19.81 vs. 64.17±31.54,P<0.05)。2组痉挛改善有效率均高于90%,组间无明显差异(91.67% vs. 95.83%,P>0.05)。2组联带运动均有改善,但无明显差异(83.33% vs. 58.33%,P>0.05)。5个自主动作相关联带运动改善方面仅发现原发性面肌痉挛患者噘嘴引起联带运动的改善有明显差异(P<0.05)。结论 BoNT-A可以显著改善原发性与面瘫后面肌痉挛患者的痉挛严重程度,在联带运动严重程度改善方面有一定疗效。原发性面肌痉挛患者噘嘴引起的联带运动在BoNT-A治疗后显著改善。
Abstract:
ObjectiveTo investigate the therapeutic difference in efficacy of botulinum toxin A(BoNT-A)injection between primary and post-paralytic hemifacial spasm patients with facial synkinesis.Methods 12 Patients presented as post-paralytic hemifacial spasm combined with synkinesis from January 2009 to July 2018 were selected for analyzing. With a ratio of 1:2, 24 primary hemifacial spasm patients combined with synkinesis were included according to the similar gender as post-paralytic group. Moreover, improvement of spasm and synkinesis were analyzed in this study.Results Except a significantly higher satisfaction score(84.79±19.81 vs. 64.17±31.54,P<0.05)seen in primary hemifacial spasm patients, latency(4.38±2.17 vs. 4.67±4.14 days), duration of effect(3.83±2.94 vs. 4.96±2.48 days), dosage of injection(31.35±12.30 vs. 26.98±8.75 U)were similar in both groups after BoNT-A treatment(P>0.05). Moreover, both group showed a high efficient rate more than 90%(91.67% vs. 95.83%,P>0.05)of improvement of spasm after BoNT-A treatment. As for improvement of synkinesis, post paralytic hemifacial spasm showed a higher efficient rate(83.33% vs. 58.33%,P>0.05)of severity. As for 5 voluntary facial movement related synkinesis, significant improvement of pouting induced synkinesis was seen in primary group(P<0.05).Conclusion BoNT-A was an efficient and safe intervention not only improving the severity of spasm, but also decreasing the severity of synkinesis. Pouting induced synkinesis was significantly improved in primary group.

参考文献/References:


[1] Green KE,Rastall D,Eggenberger E.Treatment of blepharospasm/hemifacial spasm[J].Curr Treat Options Neurol,2017,19(11):41.
[2] Lu AY,Yeung JT,Gerrard JL,et al.Hemifacial spasm and neurovascular compression[J].ScientificWorldJournal,2014,2014(1-7):349319.
[3] Husseman J,Mehta RP.Management of synkinesis[J].Facial Plast Surg,2008,24(2):242-249.
[4] Kollewe K,Mohammadi B,Dengler R,et al.Hemifacial spasm and reinnervation synkinesias:long-term treatment with either Botox or Dysport[J].J Neural Transm(Vienna),2010,117(6):759-763.
[5] Colosimo C,Bologna M,Lamberti S,et al.A comparative study of primary and secondary hemifacial spasm[J].Arch Neurol,2006,63(3):441-444.
[6] Cohen DA,Savino PJ,Stern MB,et al.Botulinum injection therapy for blepharospasm: a review and report of 75 patients[J].Clin Neuropharmacol,1986,9(5):415-429.
[7] Ross BR,Fradet G,Nedzelski JM.Development of a sensitive clinical facial grading system[J].Eur Arch Otorhinolaryngol,1994,114(3):S180-S181.
[8] Barbosa E,Takada LT,Goncalves LR,et al.Botulinum toxin type A in the treatment of hemifacial spasm:an 11-year experience[J].Arq Neuropsiquiatr,2010,68(4):502-505.
[9] Mette Batisti JP,Fadini Kleinfelder AD,Moro A,et al.Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated[J].Arq Neuropsiquiatr,2017,75(2):87-91.
[10] Choe WJ,Kim J.Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm[J].Acta Otolaryngol,2016,136(9):952-955.
[11] Wang L,Hu XY,Dong HJ,et al.Clinical features and treatment status of hemifacial spasm in China[J].Chin Med J(Engl),2014,127(5):845-849.
[12] Fujiwara K,Furuta Y,Nakamaru Y,et al.Comparison of facial synkinesis at 6 and 12 months after the onset of peripheral facial nerve palsy[J].Auris Nasus Larynx,2015,42(4):271-274.
[13] Xiao L,Pan Y,Zhang X,et al.Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment[J].Neurol Sci,2016,37(11):1807-1813.
[14] Maria CM,Kim J.Individualized management of facial synkinesis based on facial function[J].Acta Otolaryngol,2017,137(9):1010-1015.
[15] Markey JD,Loyo M.Latest advances in the management of facial synkinesis[J].Curr Opin Otolaryngol Head Neck Surg,2017,25(4):265-272.

备注/Memo

备注/Memo:
基金项目:上海市市级医疗卫生优秀学科带头人培养计划资助(2017BR029); 国家重点研发计划资助(2018YFC1314700); 中央高校基本科研业务费专项资金资助
作者单位:200065 上海,同济大学附属同济医院神经内科[杨明娜 苏俊辉 张小龙 潘有贵 肖莉彬 何怡婧 李丽喜 靳令经(通信作者)]
更新日期/Last Update: 2019-02-20